New hope for advanced prostate cancer: drug combo trial launches

NCT ID NCT07590934

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This study is testing two experimental drugs (AZD9574 and AZD2265) together in people with metastatic prostate cancer that has spread beyond the prostate. The goal is to see if the combination is safe and can shrink tumors or lower PSA levels. About 152 adults whose cancer has not responded to standard treatments will take part. The trial is not yet recruiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    NOT_YET_RECRUITING

    Encino, California, 91436, United States

  • Research Site

    RECRUITING

    South Pasadena, California, 91030, United States

  • Research Site

    RECRUITING

    Miami, Florida, 33165, United States

  • Research Site

    NOT_YET_RECRUITING

    Tampa, Florida, 33612, United States

  • Research Site

    NOT_YET_RECRUITING

    Metairie, Louisiana, 70006, United States

  • Research Site

    NOT_YET_RECRUITING

    Minneapolis, Minnesota, 55455, United States

  • Research Site

    NOT_YET_RECRUITING

    Omaha, Nebraska, 68130, United States

  • Research Site

    NOT_YET_RECRUITING

    New York, New York, 10065, United States

  • Research Site

    NOT_YET_RECRUITING

    Portland, Oregon, 97239, United States

  • Research Site

    NOT_YET_RECRUITING

    Houston, Texas, 77030, United States

  • Research Site

    NOT_YET_RECRUITING

    North Adelaide, 5000, Australia

  • Research Site

    NOT_YET_RECRUITING

    Essen, 45147, Germany

  • Research Site

    NOT_YET_RECRUITING

    Jena, 07747, Germany

  • Research Site

    NOT_YET_RECRUITING

    Rostock, 18057, Germany

  • Research Site

    NOT_YET_RECRUITING

    Tübingen, 72076, Germany

  • Research Site

    NOT_YET_RECRUITING

    Bergamo, 24127, Italy

  • Research Site

    NOT_YET_RECRUITING

    Meldola, 47014, Italy

  • Research Site

    NOT_YET_RECRUITING

    Milan, 20133, Italy

  • Research Site

    NOT_YET_RECRUITING

    Milan, 20141, Italy

  • Research Site

    NOT_YET_RECRUITING

    Roma, 00168, Italy

  • Research Site

    NOT_YET_RECRUITING

    Seoul, 03080, South Korea

  • Research Site

    NOT_YET_RECRUITING

    Seoul, 03722, South Korea

  • Research Site

    NOT_YET_RECRUITING

    Seoul, 06351, South Korea

  • Research Site

    NOT_YET_RECRUITING

    Seoul, 06591, South Korea

  • Research Site

    NOT_YET_RECRUITING

    Seoul, 5505, South Korea

  • Research Site

    NOT_YET_RECRUITING

    Barcelona, 08028, Spain

  • Research Site

    NOT_YET_RECRUITING

    L'Hospitalet de Llobregat, 08908, Spain

  • Research Site

    NOT_YET_RECRUITING

    Madrid, 28031, Spain

  • Research Site

    NOT_YET_RECRUITING

    Madrid, 28041, Spain

  • Research Site

    NOT_YET_RECRUITING

    Pamplona, 31008, Spain

  • Research Site

    NOT_YET_RECRUITING

    Fulham, SW3 6JJ, United Kingdom

  • Research Site

    NOT_YET_RECRUITING

    Guildford, CU2 7XX, United Kingdom

  • Research Site

    NOT_YET_RECRUITING

    London, WC1E 6DB, United Kingdom

  • Research Site

    NOT_YET_RECRUITING

    Newcastle upon Tyne, NE7 7DN, United Kingdom

  • Research Site

    NOT_YET_RECRUITING

    Oxford, OX3 7LE, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.